Development of Vancomycin Initial Dosage Guidelines to Achieve New Target Ranges
![]() |
Yoo, Jae-Young
(Department of Pharmacy, Samsung Medical Center)
Kim, Jung-Hyun (Department of Pharmacy, Samsung Medical Center) Lee, Yong-Won (Department of Pharmacy, Samsung Medical Center) Kim, Eun-Yeong (College of Pharmacy, Chungnam National University) Sohn, Kie-Ho (Department of Pharmacy, Samsung Medical Center) |
1 | Moise-Broder PA, Sakoulas G, Eliopoulos GM, et al., Accessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus if predictive of failure of vancomycin therapy. Clin Infect Dis 2004; 38: 1700-1705. DOI ScienceOn |
2 | Wang JT, Fang CT, Chen YC, et al., Necessity of a loading dose when using vancomycin in critically ill patients. J Antimicrob Chemother 2001. 47: 239-246. DOI |
3 | Rybak M, Lomaestro B, Rotschafer JC, et al., Therapeutic monitoring of vancomycin in adult patients: A consensus review of the American Society of Health-System Pharmacists, the Infectious Disease Society of America, and the Society of Infectious Diseases Pharmasists. Am J Health-Syst Pharm 2009; 66: 82-98. DOI ScienceOn |
4 | Sakoulas G, Gold HS, Cohen RA, et al., Effects of prolonged vancomycin administration on methicillin-resistant Staphylococcus aureus(MRSA) in a patient with recurrent bacteremia. J Antimicrob Chemother 2006; 57: 699-704. DOI ScienceOn |
5 | Howden BP, Ward PB, Charles PG, et al., Treatment outcomes of serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin Infect Dis 2004; 38: 521-8. DOI ScienceOn |
6 | Joint Formulary Committee : British National Formulary, Fifty-sixth Edition. London: British Medical Association and Royal Pharmaceutical Society of Great Britain, September 2008. |
7 | Matzke GR, McGory RW, Halstenson CE, et al., Pharmacokinetics of vancomycin in patients with various degrees of renal function. Antimicrobial Agents and Chemotherapy 1984; Apr: 433-437. DOI ScienceOn |
8 | Pea F, Furlanut M, Negri C, et al. Prospectively validated dosing nomograms for maximizing the pharmacodynamics of vancomycin administered by continuous infusion in the critically ill patients: the Optivanco study. Antimicrob Agents Chemother 2009; Feb 17. DOI ScienceOn |
9 | Thomson AH, Staatz CE, Tobin CM, et al., Development and evaluation of vancomycin dosage guidelines designed to achieve new target concentrations. J Antimicrob Chemother 2009; Mar 19. DOI ScienceOn |
10 | Michael EW. Basic Clinical Pharmacokinetics, 4th ed. New York: Lippincott Williams & Wilkins, 2004; 451-476. |
11 | Yasuhara M, Iga T, Zenda H, et al., Population pharmacokinetics of vancomycin in Japanese adult patients. Ther Drug Monit 1998; 20: 139-148. DOI ScienceOn |
12 | Rodvold KA, Blum RA, Fischer JH, et al., Vancomycin pharmacokinetics in patients with varying degrees of renal function. Antimicorb Agents Chemother 1988; 32: 848- 852. DOI ScienceOn |
13 | Moellering RC Jr. Vancomycin: a 50-year reassessment. Clin Infect Dis 2006; 42(suppl 1): S3-4. DOI |
14 | Rybak MJ. The pharmacokinetic and pharmacodynamic properties of vancomycin. Clin Infect Dis 2006; 42(suppl 1): S35-39. DOI |
15 | Craig WA. Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides, and linezolid. Infect Dis Clin North Am 2003; 17: 479-501. DOI ScienceOn |
16 | Geraci J. Vancomycin. Mayo Clin Proc 1977; 52: 631-634. |
17 | Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antimicrobial dosing of mice and men. Clin Infect Dis 1998; 26: 1-10. DOI ScienceOn |
18 | Drusano GL. Antimicrobial pharmacodynamics: critical interactions of bug and drug. Nature Rev Microbiol 2004; 2: 289-300. DOI ScienceOn |
19 | Rybak MJ. Pharmacodynamics: relation to antimicrobial resistance. Am J Med 2006; 119(6, suppl 1): S37-44. DOI ScienceOn |
20 | American Thoracic Society, Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquried, ventilator-associated, and healthcareassociated pneumonia: specific evaluation of vancomycin pharmacokinetic indices. Chest 2006; 130: 947-955. DOI ScienceOn |
21 | Boffi El, Amari E, Vuagnat A, et al., High versus standard dose vancomycin for osteomyelitis. Scand J Infect Dis 2004; 36: 712-717 |
22 | Moore MR, Perdreau-Remington F, Chamers HF. Vancomycin treatment failure associated with heterogeneous vancomycin-intermediate Stapylococcus aureus in a patient with endocarditis and in the rabbit model of endocarditis. Antimicrob Agents Chemother 2003; 47: 1262-1266. DOI ScienceOn |
![]() |